产品
编 号：F751435
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2350298-92-7
产品详情
生物活性：
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.
体内研究：
Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice.Animal Model:MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model
Dosage:5 mg/kg
Administration:IP, twice a week, 3weeks
Result:Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group.
体外研究：
Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies.Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages.Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902).Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade.
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.
体内研究：
Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice.Animal Model:MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model
Dosage:5 mg/kg
Administration:IP, twice a week, 3weeks
Result:Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group.
体外研究：
Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies.Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages.Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902).Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备